Filing identity and reporting period
The supplied filing is MEI Pharma, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2017, not a filing for Lite Strategy, Inc. or 2016 Q1. The financial comparisons are for the three months ended September 30, 2017 and 2016.
Business context
MEI Pharma is a clinical-stage oncology company. Its pipeline includes pracinostat, ME-401, voruciclib and ME-344. Helsinn holds worldwide development and commercialization rights to pracinostat and primarily funds its development. MEI obtained worldwide rights to voruciclib from Presage in September 2017 and is responsible for its development costs.
Financial performance and position
| Metric | Three months ended September 30, 2017 | Prior-year period |
|---|---|---|
| Revenue | $0.283 million | $1.096 million |
| Operating expenses | $9.170 million | $5.420 million |
| Operating loss | $8.887 million | $4.324 million |
| Net loss | $8.788 million | $4.270 million |
| Basic and diluted net loss per share | $0.24 | $0.12 |
| Cash used in operating activities | $6.562 million | Cash provided: $8.773 million |
At September 30, 2017, cash, cash equivalents and short-term investments totaled $47.023 million, down from $53.565 million at June 30. Short-term investments were U.S. government securities. Current assets were $47.664 million and current liabilities were $4.465 million. The balance sheet reports no debt; the filing does not provide a separate debt balance. No conventional product-sales margin is presented; R&D revenue was recognized under the Helsinn agreement, with associated cost of $0.618 million.
Material changes versus the prior-year quarter
- Revenue fell to $0.283 million from $1.096 million, while net loss increased to $8.788 million from $4.270 million.
- Research and development expense increased to $6.064 million from $1.646 million, mainly reflecting $2.9 million of voruciclib license-related expense, higher ME-401 manufacturing and ME-344 trial costs. General and administrative expense declined to $2.488 million from $2.680 million.
- Operating cash flow shifted from $8.773 million provided to $6.562 million used. The prior-year inflow included a $15 million Helsinn upfront payment.
- Financing cash inflow was only $0.020 million, versus $4.212 million in the prior-year quarter, which included Helsinn’s equity investment.
Outlook, risks and unusual items
Management expected the $47.0 million of cash and short-term investments to fund operations into calendar 2019, while anticipating operating losses and negative operating cash flows for the foreseeable future. Management said additional financing or strategic transactions would be needed at some point; changes in development plans could affect the runway.
Development milestones include the start of a Helsinn-funded Phase III pracinostat AML study in July 2017, an ME-401 dose-escalation study, and plans to initiate Phase I/II voruciclib studies. MEI expected initial MDS study data and ME-344 combination-study interim results in the first half of 2018, and planned to present ME-401 long-term data in that period. These are expectations, not assurances of results.
Under the Presage agreement, MEI paid $1.9 million upfront, accrued a further $1.0 million near-term payment, and may owe up to $2.0 million upon dosing the first patient in a registration trial. The agreement includes up to $179 million of additional development, regulatory and commercial milestones and mid-single-digit tiered royalties. The filing also cites up to $75.2 million of potential S*Bio milestones; a $0.2 million cash payment and shares valued at $0.5 million were issued after the first patient dosing in a Phase III trial.
Other considerations include a $1.4 million remaining office lease obligation, 3,230,202 warrants exercisable at $3.12 per share and expiring in December 2017, and a shelf registration with $150 million of securities available. The company warns of clinical-development, regulatory, financing, third-party and intellectual-property risks. It reported no legal proceedings and concluded disclosure controls were effective.
Investor verification points
- Confirm the intended issuer and period: the supplied document identifies MEI Pharma and September 30, 2017, despite request metadata naming Lite Strategy and 2016 Q1.
- Review cash burn, assumptions behind management’s runway into calendar 2019, and potential financing needs.
- Track clinical-trial progress, results, funding responsibilities and timing for pracinostat, ME-401, voruciclib and ME-344.
- Assess potential Presage and S*Bio milestone, royalty and other obligations against available liquidity.
- Check dilution and capital-market exposure, including outstanding warrants and the available shelf registration.